A Randomized Phase II Clinical Trial of Talazoparib Maintenance Therapy in Triple-negative Breast Cancer Patients Who Showed Platinum-sensitivity on First- or Second-line Platinum-based Chemotherapy
Latest Information Update: 07 Mar 2024
Price :
$35 *
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Jun 2023 According to trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology, as of now, 23 of planned 206 patients have been enrolled.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 17 Feb 2021 New trial record